Runben Biotechnology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,571	1,544	1,317	1,032	855.65	581.91
Other Revenue	0.96	0.96	0.77	0.66	0.44	0.24
Revenue	1,572	1,545	1,318	1,033	856.09	582.15
Revenue Growth (YoY)	12.96%	17.19%	27.61%	20.66%	47.06%	31.46%
Cost of Revenue	654.26	646.61	553.2	453.34	393.28	275.75
Gross Profit	917.6	898.19	764.98	579.62	462.81	306.4
Selling, General & Admin	531.95	521.03	411.86	301.68	257.21	155.39
Research & Development	38.28	37.59	35.07	25.69	19.51	13.6
Other Operating Expenses	11.86	11.45	14.49	9.42	8.77	6.83
Operating Expenses	582.15	570.31	461.89	336.99	285.47	175.82
Operating Income	335.45	327.87	303.08	242.62	177.34	130.58
Interest Expense	-0.07	-0.08	-0.13	-0.26	-0.43	-0.54
Interest & Investment Income	31.92	30.56	34.84	16.4	7.18	6.09
Currency Exchange Gain (Loss)	0.05	0.05	0	-	-	0.24
Other Non Operating Income (Expenses)	-0.16	-0.17	-0.14	-0.05	-0.16	-0.05
EBT Excluding Unusual Items	367.19	358.23	337.66	258.72	183.94	136.32
Gain (Loss) on Sale of Investments	-1.57	0.84	3.59	-	-	-
Gain (Loss) on Sale of Assets	0.08	0.08	-0.6	0.07	0.05	0
Asset Writedown	0.26	-	-	-	-	-
Other Unusual Items	3.1	3.1	11.36	9.13	4.29	5.31
Pretax Income	369.06	362.25	352	267.93	188.27	141.63
Income Tax Expense	46.12	47.75	51.84	41.9	28.23	20.98
Net Income	322.94	314.5	300.16	226.03	160.04	120.65
Net Income to Common	322.94	314.5	300.16	226.03	160.04	120.65
Net Income Growth	4.55%	4.78%	32.80%	41.23%	32.66%	27.38%
Shares Outstanding (Basic)	404	403	406	353	341	335
Shares Outstanding (Diluted)	404	403	406	353	341	335
Shares Change (YoY)	-0.87%	-0.60%	14.85%	3.71%	1.61%	9.69%
EPS (Basic)	0.80	0.78	0.74	0.64	0.47	0.36
EPS (Diluted)	0.80	0.78	0.74	0.64	0.47	0.36
EPS Growth	5.47%	5.41%	15.63%	36.17%	30.56%	16.13%
Free Cash Flow	175.92	187.42	183.02	238.87	124.67	-13.38
Free Cash Flow Per Share	0.43	0.47	0.45	0.68	0.37	-0.04
Dividend Per Share	0.460	0.460	0.410	0.170	-	-
Dividend Growth	12.20%	12.20%	141.18%	-	-	-
Gross Margin	58.38%	58.14%	58.03%	56.11%	54.06%	52.63%
Operating Margin	21.34%	21.22%	22.99%	23.49%	20.71%	22.43%
Profit Margin	20.54%	20.36%	22.77%	21.88%	18.70%	20.72%
Free Cash Flow Margin	11.19%	12.13%	13.88%	23.13%	14.56%	-2.30%
EBITDA	356.18	348.43	322.92	262.46	194.59	138.59
EBITDA Margin	22.66%	22.55%	24.50%	25.41%	22.73%	23.81%
D&A For EBITDA	20.73	20.55	19.84	19.84	17.25	8.01
EBIT	335.45	327.87	303.08	242.62	177.34	130.58
EBIT Margin	21.34%	21.22%	22.99%	23.49%	20.71%	22.43%
Effective Tax Rate	12.50%	13.18%	14.73%	15.64%	14.99%	14.82%
Revenue as Reported	1,572	1,545	1,318	1,033	856.09	582.15
Advertising Expenses	-	419.37	320.61	218.47	187.47	107.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.